Clinical Trial Poster Presentation of Naptumomab at AACR 2023 Annual Meeting

Apr 11, 2023 16:30 (CEST)

Lund, Sweden — April 11, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced the acceptance of an abstract at the American Association for Cancer Research (AACR) 2023 Annual Meeting in Orlando, Florida, April 14-19, 2023.

The poster will present the results of safety and preliminary activity in the phase 1b dose escalation trial of naptumomab (naptumomab estafenatox, NAP) combined with durvalumab in patients with advanced or metastatic solid tumors. The study is conducted by Active Biotech’s partner NeoTX.

Details on the presentation:

  • Abstract Title: Safety and Preliminary Activity of Naptumomab Estafenatox (NAP) and Durvalumab in Patients with Advanced or Metastatic Solid Tumors: Interim results from a Phase 1b Trial
  • Abstract Number: CT205
  • Location: Poster Section 46
  • Poster Board Number: 18
  • Session Title: Phase I Clinical Trials
  • Session Date & Time: Tuesday April 18, 2023, 9:00 AM – 12:30 PM Eastern Time (ET)

For further information, please contact:

Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com

About Active Biotech

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II-study for treatment of non-infectious uveitis. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.

About NeoTX

NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox  is currently in clinical development for advanced solid tumors (clinicaltrials.gov/NCT039883954 and NCT04880863). Please visit www.neotx.com for more information.

Naptumomab was licensed from Active Biotech to NeoTX Therapeutics Ltd in 2016. NeoTX is responsible for the global development and commercialization of naptumomab for the treatment of cancer under the license agreement.

Attachments

Clinical Trial Poster Presentation of Naptumomab at AACR 2023 Annual Meeting